MIR218-1
MIR218-1 (microRNA 218-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Pancreatic ductal adenocarcinoma.
Overview
UniProt has no function text for this gene; HGNC names it "microRNA 218-1".
CIViC holds 3 clinical evidence items and 0 assertions across 2 variants.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MIR218-1 (microRNA 218-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Pancreatic ductal adenocarcinoma.
- 1 · What it is
MIR218-1 (microRNA 218-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Pancreatic ductal adenocarcinoma.
- 2 · What goes wrong in cancer
UniProt has no function text for this gene; HGNC names it "microRNA 218-1". Locus 4p15.31 (HGNC).
- 3 · How drugs use it
No product in this corpus aims at MIR218-1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:31595 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); CIViC gene MIR218-1 (3 evidence items, 0 assertions, 2 variants; diseases: Colorectal Cancer, Pancreatic Cancer (GraphQL API, CC0))
Biology
UniProt has no function text for this gene; HGNC names it "microRNA 218-1". Locus 4p15.31 (HGNC).
- Colorectal cancer: CIViC evidence names this disease
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 3 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"MIR218-1" OR ABSTRACT:"MIR218-1" OR TITLE:"microRNA 218-1" OR ABSTRACT:"microRNA 218-1" OR TITLE:"hsa-mir-218-1" OR ABSTRACT:"hsa-mir-218-1" OR TITLE:"MIRN218-1" OR ABSTRACT:"MIRN218-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MIR218-1, not a curated reading list.